Case Studies

Case Studies

First-in-Human Dose Predictions

A modRNA as a Lipid Nanoparticle to treat Crigler-Najjar Syndrome Type 1

Clinical Candidate Selection

Immuno-modulation in Chronic Inflammation

Phase-1 Interim Analysis

Immuno-modulation in Chronic Inflammation

Early Feasibility Assessment

Optimizing Design of a Bispecific Therapeutic Antibody using QSP

Predicting Optimal Drug Parameters and Doses

QSP approaches accelerate lead generation and optimization of a PD-1 x TIM-3 therapeutic in I/O

Antibody-Drug Conjugate (ADC) Design

Computational Exploration of ADC PK